1. Home
  2. AGMB vs CERS Comparison

AGMB vs CERS Comparison

Compare AGMB & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AgomAb Therapeutics NV American Depositary Shares

AGMB

AgomAb Therapeutics NV American Depositary Shares

N/A

Current Price

$5.54

Market Cap

576.2M

Sector

Health Care

ML Signal

N/A

Logo Cerus Corporation

CERS

Cerus Corporation

N/A

Current Price

$1.86

Market Cap

465.5M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
AGMB
CERS
Founded
2017
1991
Country
Belgium
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
576.2M
465.5M
IPO Year
2024
1996

Fundamental Metrics

Financial Performance
Metric
AGMB
CERS
Price
$5.54
$1.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
★ $37.67
$5.13
AVG Volume (30 Days)
297.3K
★ 2.5M
Earning Date
12-01-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.27
EPS
★ N/A
N/A
Revenue
N/A
★ $51,326,000.00
Revenue This Year
N/A
$17.63
Revenue Next Year
N/A
$8.79
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 30.68
52 Week Low
$5.50
$1.59
52 Week High
$17.82
$3.47

Technical Indicators

Market Signals
Indicator
AGMB
CERS
Relative Strength Index (RSI) 23.66 38.50
Support Level N/A $1.73
Resistance Level $9.55 $2.04
Average True Range (ATR) 0.69 0.18
MACD -0.04 -0.02
Stochastic Oscillator 5.17 2.14

Price Performance

Historical Comparison
AGMB
CERS

About AGMB AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.

Share on Social Networks: